SkyePharma received a boost yesterday on news that its US marketing partner, Critical Therapeutics, has rolled out its Zyflo CR extended-release tablets for the prevention and chronic treatment of asthma.
According to the company, Critical Therapeutics and its co-promotion partner Dey LP (an affiliate of Merck KGaA) plan to target around 18,000 specialists and primary care physicians throught the USA with a 240-strong salesforce.
Part of their sales ammunition will be the fact that Zyflo CR (zileuton) has been included in new guidelines issued by the USA’s National Asthma Education and Prevention Programme.
Zyflo CR and Zyflo are the only US Food and Drug Administration-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, which work interrupting white blood cell activity contributing to the symptoms of asthma.
Zyflo CR uses SkyePharma’s proprietary Geomatrix drug delivery technology, which controls the amount and rate of drug released into the body and, according to chief executive Frank Condella, “will provide physicians with an additional treatment option for the many asthmatics who have not been able to gain symptomatic control despite their current therapies.”